Format

Send to

Choose Destination
See comment in PubMed Commons below
Prim Care. 1999 Dec;26(4):895-915.

The use of insulin secretagogues in the treatment of type 2 diabetes.

Author information

1
Department of Internal Medicine and Infectious Disease, Campbell University School of Pharmacy, Durham, North Carolina 27710, USA.

Abstract

Secretatogues are a class of agents that achieve their hypoglycemic effects through stimulating insulin release. They include the sulfonylureas, repaglinide, and the investigational agent glucagon-like peptide. The secretagogue agents have been studied extensively as monotherapy and in conjunction with other classes of oral agents, including alpha-glucosidase inhibitors, bijuanides, and thiazolidinediones, for the treatment of type 2 diabetes. This article reviews the pharmacodynamic and pharmacokinetic differences of the secretagogues, as well as the most recent clinical trials. Such information should be helpful when deciding which agent or agents will yield the best glycemic control for an individual patient.

PMID:
10523467
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center